Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by TFDA

1.Date of occurrence of the event:2022/11/14 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). It binds to PD-L1 and CD137, and induces T-cell activation, as well as cancer cell killing, in a target-dependent manner with reduced systemic cytokine release. […]

This article is password protected.

To view the content, please enter your password in the field below